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After an initial burst of cell proliferation, the type 1
insulin-like growth factor receptor (IGF-IR) induces
granulocytic differentiation of 32D IGF-IR cells, an in-
terleukin-3-dependent murine hemopoietic cell line de-
void of insulin receptor substrate-1 (IRS-1). The com-
bined expression of the IGF-IR and IRS-1 (32D IGF-IR/
IRS-1 cells) inhibits IGF-I-mediated differentiation, and
causes malignant transformation of 32D cells. Because
of the role of IRS-1 in changing the fate of 32D IGF-IR
cells from differentiation (and subsequent cell death) to
malignant transformation, we have looked for differ-
ences in IGF-IR signaling between 32D IGF-IR and 32D
IGF-IR/IRS-1 cells. In this report, we have focused on
p70S6K, which is activated by the IRS-1 pathway. We find
that the ectopic expression of IRS-1 and the inhibition of
differentiation correlated with a sustained activation of
p70S6K and an increase in cell size. Phosphorylation in
vivo of threonine 389 and, to a lesser extent, of threonine
421/serine 424 of p70S6K seemed to be a requirement for
inhibition of differentiation. A role of IRS-1 and p70S6K
in the alternative between transformation or differenti-
ation of 32D IGF-IR cells was confirmed by findings that
inhibition of p70S6K activation or IRS-1 signaling, by
rapamycin or okadaic acid, induced differentiation of
32D IGF-IR/IRS-1 cells. We have also found that the ex-
pression of myeloperoxidase mRNA (a marker of differ-
entiation, which sharply increases in 32D IGF-IR cells),
does not increase in 32D IGF-IR/IRS-1 cells, suggesting
that the expression of IRS-1 in 32D IGF-IR cells causes
the extinction of the differentiation program initiated
by the IGF-IR, while leaving intact its proliferation
program.
The type 1 insulin-like growth factor receptor (IGF-IR),1
activated by its ligands plays an important role in the growth of
cells in at least four different ways. It is mitogenic, both in vivo
and in vitro, it is quasi-obligatory for transformation, it can
protect cells from a variety of apoptotic injuries, and it can also
induce differentiation in certain types of cells (1). The fact that
the IGF-IR can induce cell differentiation (that eventually re-
sults in inhibition of growth and cell death) is in clear contra-
diction to its other properties, which are more of a growth-
promoting type. The mechanism by which the IGF-IR switches
from one signaling to another is in itself of considerable
interest.
We have recently shown that, in the case of the IGF-IR, the
choice between stimulation of cell proliferation or differentia-
tion depends on the availability of the immediate substrates of
the IGF-IR (2). In those experiments, we used as a model 32D
cells (3), which are diploid murine hemopoietic cells. 32D cells
have an absolute requirement for interleukin-3 (IL-3) for
growth, and undergo apoptosis when IL-3 is withdrawn (4–6).
IGF-I (7, 8) or overexpression of the IGF-IR (9–11) prevent
apoptosis caused by IL-3 withdrawal. Furthermore, IGF-I can
induce in these cells a differentiation program along the gran-
ulocytic pathway (2). A characteristic of 32D cells is that they
are devoid of insulin receptor substrate-1 (IRS-1) and IRS-2
(12–14), whereas Shc proteins are strongly expressed. This
unbalance between the two major substrates of the IGF-IR
suggested that the absence of IRS-1 could play a role in the
induction of differentiation by IGF-I in 32D IGF-IR cells. In-
deed, re-introduction of IRS-1 in these cells resulted in inhibi-
tion of IGF-I-mediated differentiation, which was also inhibited
by a dominant negative mutant of Shc (2). It seems therefore
that proliferation or differentiation of 32D IGF-IR cells de-
pends on the availability of substrates, with IRS-1 favoring
proliferation and Shc proteins favoring differentiation. An im-
portant aspect of those experiments was that the IGF-IR, by
itself, causes 32D cells to grow very rapidly for the first 48 h.
During this 48-h period, there is no appreciable difference in
the rate of growth between 32D IGF-IR cells and 32D IGF-IR/
IRS-1 cells (Refs. 2 and 11, and this paper). This is in agree-
ment with the established fact that differentiation of cells,
especially hemopoietic cells, requires a short period of cell
proliferation (5, 15). A typical example is the granulocyte col-
ony-stimulating factor, which induces both the proliferative
and the differentiating programs, with the latter eventually
prevailing.
In previous papers (2, 10), we reported that IRS-1 greatly
increases PI 3-kinase and Akt activation in 32D cells. Since
this pathway connects with the activation of p70S6K (16), we
have focused, in the present investigation, on p70S6K (17). We
have found that sustained activation of p70S6K (in vivo phos-
phorylation of threonine 389 and threonine 421/serine 424)
correlates with the inhibition of differentiation (and therefore
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with the transformed phenotype). In addition, rapamycin and
okadaic acid (OKA), both of which inhibit p70S6K activation,
induce differentiation of 32D IGF-IR/IRS1 cells. Inhibition of
differentiation is accompanied by an increase in size of the
cells, which is in agreement with the effect of homologues of
IRS-1 (18) and p70S6K (19) on cell size in Drosophila. By deter-
mining the expression of myeloperoxidase (MPO) mRNA, we
also find that the differentiation program is already activated
in 32D IGF-IR cells while they are still actively proliferating.
MPO mRNA, however, does not increase in 32D IGF-IR/IRS1
cells. These results suggest that IRS-1 may indeed extinguish
the differentiation program of 32D IGF-IR cells (without affect-
ing its proliferative program), and that this effect may be
mediated by the sustained activation of p70S6K.
Finally, we report here that 32D IGF-IR/IRS1 cells, in addi-
tion to be able to grow in the absence of IL-3 without differen-
tiating, can also form tumors in mice. These latter experiments
confirm and extend previous reports that overexpression of
IRS-1 results in transformation (20, 21).
EXPERIMENTAL PROCEDURES
Cell Lines—32D IGF-IR cells were obtained from the murine hema-
topoietic cell line 32D clone 3 (3) by stable transfection with the human
wild type IGF-I receptor. 32D IGF-IR/IRS-1 are 32D IGF-IR overex-
pressing the wild type IRS-1 and 32D IGF-IR/vector are 32D IGF-IR
cells stably transfected with the empty vector used to deliver IRS-1.
These three cell lines are mixed populations obtained by retroviral
infection and have already been described by Valentinis et al. (2) and
Peruzzi et al. (11). Cells were grown in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum (Life Technolo-
gies, Inc.), 10% WEHI cell conditioned medium as a source of IL-3 and
the required antibiotics to maintain the selective pressure (250 mg/ml
G418, from Life Technologies, Inc., or 250 mg/ml hygromycin, from
Calbiochem). For brevity, the WEHI cell conditioned medium will be
referred to as IL-3.
Growth and Differentiation Analysis—Cells exponentially growing
were collected, washed three times, and seeded in IL-3-free medium
(RPMI 1640 medium containing only 10% heat-inactivated fetal bovine
serum) supplemented with 50 ng/ml IGF-I. In some experiments, in-
hibitors (10 nM or 20 nM okadaic acid (Sigma), or 2.5 or 10 ng/ml
rapamycin (Sigma)) were added. Cells were seeded at a density of 5 3
104 cells/ml. After 4 and 6 days, viable cells were counted by trypan blue
exclusion (Life Technologies, Inc.) and cytospins were performed for
morphological analysis. To establish the ability for IL-3-independent
growth, cells from the same experiments at day four were re-plated in
fresh IL-3-free medium with IGF-I (50 ng/ml) at a density of 5 3 104
cells/ml. Cells were counted by trypan blue exclusion after 4 additional
days (for a total of 8 days of culture). To evaluate the degree of granu-
locytic differentiation, cytospins were stained with Wright-Giemsa and
the cells in the different stages of differentiation counted at the micro-
scope. Differentiation was expressed as percentage of bands and poly-
morphonuclear cells in the total number of scored cells.
Immunoblots—For the detection of phosphorylated proteins, expo-
nentially growing cells were washed three times and incubated in
serum-free medium (RPMI 1640 medium supplemented with 0.1% bo-
vine serum albumin (Sigma)) for 4 h before stimulation with 20 ng/ml
IGF-I (Life Technologies, Inc.). When inhibitors were used, cells were
pre-incubated with the inhibitors for 1 h (okadaic acid) or 15 min
(rapamycin) before stimulation with IGF-I. At the desired time point,
cells were collected, washed with cold phosphate-buffered saline, and
resuspended in lysis buffer in ice for 30 min. Cell lysates were clarified
by centrifugation at 13,000 rpm for 15 min, and equal amounts of
proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose filter. For immuno-
blotting, membranes were blocked with 5% nonfat dry milk in buffer
consisting of 10 mM Tris (pH 8.0), 150 mM NaCl, and 0.1% Tween 20
overnight at 4 °C and probed with the indicated primary antibodies,
followed by incubation with horseradish peroxidase-conjugated anti-
rabbit or anti-mouse immunoglobulin (Oncogene Science). Blots were
developed with the enhanced chemiluminescence system according to
the manufacturer’s instruction (Amersham Pharmacia Biotech)
Antibodies—The phosphorylation of specific amino acids in p70S6K
(phospho-Thr389, phospho-Thr421/Ser424, and phospho-Ser411) was de-
tected with antibodies purchased from New England Biolabs. The total
amount of p70S6K loaded was monitored after stripping of the filters by
immunoblotting with an anti p70S6K antibody (C-18, Santa Cruz). IRS-1
was detected with an antibody to its carboxyl-terminal (Upstate Bio-
technology, Inc., Lake Placid, NY).
Determination of Cell Size—Exponentially growing cells were pre-
pared and seeded under the same conditions used for growth analysis.
After 24 and 48 h, cells were collected and immediately analyzed for size
and cell cycle distribution by flow cytometry. Cell size was determined
by forward scattering (FS). Cell cycle distribution was analyzed by
staining the cells with 10 mg/ml Hoechst 33342 (Molecular Probes) at
37 °C for 30 min. The cell suspension was analyzed using an Elite
ESP-EPICS flow cytometer (Coulter Corp., Hialeah, FL). Software was
Elite version 4.5.
Northern Blots—For the detection of the MPO mRNA level, exponen-
tially growing cells were prepared and seeded under the same condi-
tions used for growth analysis. At the indicated time points, cells were
collected and total RNA was extracted with the Tri-Reagent solution
(Sigma) following the manufacturer’s instructions. Ten mg of total RNA
for each sample were run on a 1% agarose formaldehyde gel, blotted
onto a nitrocellulose membrane, and hybridized with a 1.45-kilobase
myeloperoxidase cDNA fragment obtained from the pUC19-MMPO6
plasmid (a kind gift of Dr. Mauro Valtieri). The cDNA probe was labeled
with [a-32P]dCTP by the Random Primed DNA labeling kit (Roche
Molecular Biochemicals) and purified using the QuickSpinn G-50 Seph-
adex columns (Roche Molecular Biochemicals). Hybridization was per-
formed in 53 SSC, 50% formamide, 0.1% SDS, 100 mg/ml salmon sperm
DNA at 42 °C for 16 h.
Tumor Formation in Nude Mice—Cells exponentially growing were
collected, washed with phosphate-buffered saline and injected intra-
peritoneally into NIH Swiss nude mice. Each animal was injected with
10 3 106 cells and sacrificed after 6 weeks, and its organs were isolated,
weighed, and fixed in 10% buffered formalin. Histological sections of the
organs were stained with hematoxylin and eosin and examined for the
presence of infiltrating 32D cells.
RESULTS
The parental 32D cells cl. 3 (5) have an absolute requirement
for IL-3 for growth, and undergo apoptosis within 24 h after
IL-3 withdrawal (11, 13, 22). 32D IGF-IR cells and 32D IGF-
IR/IRS1 cells have been described previously (2, 11). Both 32D
IGF-IR cells and 32D IGF-IR/IRS-1 cells grow at similar rates
in IGF-I-supplemented medium for the first 48 h and do not
show any morphological sign of differentiation (2, 11). We have
monitored the deoxybromouridine labeling of these cells, grow-
ing in IGF-I, between IL-3 withdrawal (0 time) and 24 h, and
between 24 and 48 h. With both cell lines, and for both time
intervals, the labeling with deoxybromouridine was 100% (data
not shown). Thus, in the first 48 h, the two cell lines are
essentially indistinguishable, although 32D IGF-IR cells even-
tually differentiate and decrease in number.
In a previous paper (2), we had shown that tyrosyl phospho-
rylation of Shc was essentially similar in the 2 cell lines, and
that IRS-1 was tyrosyl-phosphorylated when 32D IGF-IR/IRS1
cells were stimulated with IGF-I. Soon et al. (10) have shown
that, in the absence of IRS-1, PI 3-kinase activity is undetect-
able in 32D IGF-IR cells, which survive and grow (for at least
48 h) in the presence of PI 3-kinase inhibitors (11). Ectopic
expression of IRS-1 causes a dramatic increase in PI 3-kinase
activity, and these findings of Soon et al. (10) have been con-
firmed (data not shown). Akt/PKB is strongly activated by
IGF-I in 32D IGF-IR/IRS-1 cells, but only weakly activated in
32D IGF-IR cells (2). This is not surprising since Akt activation
is markedly increased by PI 3-kinase (23–26), whose activity, in
turn, is strongly increased by IRS-1 (27). In this report, we have
focused our attention on p70S6K, whose activity is strongly
dependent on the activation of PI 3-kinase (16) and the Akt/
PKB pathway (28).
Activation of p70S6K—The analysis of the specific phospho-
rylated amino acid was performed on samples run on a 4–15%
gradient gel. We used one membrane for each blot of p70S6K
phospho-amino acid to detect a clear, specific signal without
interference from the stripping of the membrane. The time of
observation ranged from 0 to 60 min. To show the mobility shift

























of p70S6K, that is generally accepted as an indicator of p70S6K
activity (16, 29), samples were run on a 7.5% gel.
Using the antibody to phosphothreonine 421/phosphoserine
424 (30), p70S6K phosphorylation is clearly detectable, after
IGF-I stimulation, in 32D IGF-IR/IRS1 cells, but not in 32D
IGF-IR cells (Fig. 1, panel C). A difference was also detected
using an antibody to phospho-threonine 389 (Fig. 1, panel A),
which is the residue whose dephosphorylation most closely
parallels loss of kinase activity (28). The response to IGF-I
stimulation was stronger and more prolonged in 32D IGF-IR/
IRS-1 cells than in 32D IGF-IR cells. The antibody to phospho-
serine 411 of p70S6K could not detect clearly reproducible dif-
ferences between the two cell lines, after stimulation with
IGF-I (Fig. 1, panel E). Panels B, D, and F show the total
amounts of p70S6K in each lane. A mobility shift blot is shown
in Fig. 1 (panel G); a shift is detectable in both cell lines, but it
is more accentuated, especially at 30 min, and more sustained
in 32D IGF-IR/IRS-1 cells. However, it is evident that the
IGF-IR can activate p70S6K even in the absence of IRS-1.
Effect of Rapamycin on 32D IGF-IR/IRS1 Cells—Threonine
389 belongs to the group of serine/threonines of p70S6K that are
rapamycin-sensitive. In fact, they were originally considered to
be the only residues that were rapamycin-sensitive, with the
residues in the C terminus (like threonine 421 and serine 424)
considered insensitive (29, 31, 32). More recent reports have
questioned this difference (33–35). Although rapamycin actu-
ally targets mTOR, its effect is most crucial on the phosphoryl-
ation of threonine 389 (28). We reasoned that, if rapamycin-
sensitive residues are less activated in 32D IGF-IR cells, then
rapamycin, at appropriate concentrations, ought to induce dif-
ferentiation of 32D/IGF-IR/IRS1 cells.
For this purpose, 32D IGF-IR/IRS-1 cells were treated with
rapamycin in the presence of IGF-I. As shown in Fig. 2 (panel
A), the proliferation of 32D IGF-IR/IRS-1 cells is inhibited by
rapamycin (at concentrations of 2.5 and 10 ng/ml). After 4 days,
the cell number of rapamycin-treated 32D IGF-IR/IRS-1 cells is
essentially the same as in untreated 32 IGF-IR cells. At the
same time, differentiation resumes under rapamycin treat-
ment reaching the same percentage observed for 32D IGF-IR
cells (panel B).
The effect of rapamycin on p70S6K activation is summarized
in Fig. 3. In the presence of rapamycin, IGF-I fails to phospho-
rylate threonine 389 (panel A) and also, to a lesser extent,
serine 411 (panel E). Despite some difficulty in identifying the
phospho-p70S6K in panel C, one can say that rapamycin also
inhibits phosphorylation of threonine 421/serine 424. This well
known inhibition by rapamycin (see “Discussion”) was con-
firmed by mobility shift (Fig. 3, panel G). The amounts of
p70S6K protein in each lane are shown in Fig. 3 (panels B, D,
FIG. 1. Activation of p70S6K in 32D IGF-IR and 32D IGF-IR/
IRS-1 cells. Cells exponentially growing were seeded in serum-free
medium for 4 h before stimulation with 20 ng/ml IGF-I (see “Experi-
mental Procedures”). Lysates were prepared from cells at the times
indicated (in min) after IGF-I stimulation. From the same experiments,
equal amounts of proteins were subjected to three separate 4–15%
gradient gel SDS-PAGE and transferred to nitrocellulose membranes,
and each filter was blotted with a different phospho-p70S6K antibody:
phospho-Thr389 (panel A), phospho-Thr421/Ser424 (panel C), and phos-
pho-Ser411 (panel E). The membranes were stripped and re-blotted with
an anti-p70S6K antibody to assess total level of protein (panels B, D, and
F). The Western blot shown in panel G was performed on a 7.5% gel that
allows a better separation of the different phosphorylated forms of
p70S6K (mobility shift). A representative experiment is shown. Identical
results were obtained using lysates from three different experiments.
FIG. 2. Effect of rapamycin on the proliferation and differen-
tiation of 32D-derived cells. 32D IGF-IR (closed bars) and 32D IGF-
IR/IRS-1 (gray bars) were seeded in IL-3-free medium supplemented
with 50 ng/ml IGF-I at a density of 1 3 105 cells in 2 ml total volume.
32D IGF-IR/IRS-1 were also incubated with 50 ng/ml IGF-I and 2.5
ng/ml rapamycin (open bars) or 10 ng/ml rapamycin (striped bars). Cells
were analyzed for growth and differentiation after 4 days of culture.
Panel A, cell proliferation was evaluated by counting the total number
of viable cells. Panel B, Wright-Giemsa-stained cells were evaluated for
the presence of morphological characteristics of differentiation (per-
centage of bands and polymorphonuclear cells on the total number of
cells scored). A representative experiment (duplicate with range) is
shown.

























and F). These experiments confirm that the p70S6K pathway
plays a major role in determining the fate of 32D IGF-IR cells
(differentiation versus transformation).
Cell Size—It has recently been reported that, in Drosophila,
both the IRS homologue CHICO (18) and the S6 kinase homo-
logue (19) regulate cell size. We compared the cell size of 32D
IGF-IR and 32D IGF-IR/IRS1 cells, by forward scatter analysis.
Since the cell cycle distribution of a cell population affects cell
size, we also stained the cells with Hoechst 33342 and deter-
mined the cell cycle distribution. There was no difference be-
tween the two cell lines (data not shown). We then compared
cell size of subpopulations in different phases of the cell cycle
(see “Experimental Procedures”). Fig. 4 (panel A) compares the
cell size distribution generated by FACS analysis for subpopu-
lations of 32D IGF-IR and 32D IGF-IR/IRS1 cells in G1, S, and
G2/M phases of the cell cycle 48 h after IL-3 withdrawal and
supplementation with IGF-I. In all three phases of the cell
cycle, the mean of the forward scatter of 32D IGF-IR/IRS1 cells
was 15–20% higher than the mean of 32D IGF-IR cells. This
difference was highly reproducible in repeated experiments.
Similar results, but somewhat less pronounced, were detected
at 24 h after IL-3 withdrawal and IGF-I supplementation. Fig.
4 (panels B–D), shows three necessary controls. In panel B, the
subpopulation of 32D IGF-IR cells in the G2/M phase was
analyzed in either IL-3 or IGF-I. The cells have a larger size in
IL-3, indicating that 32D IGF-IR cells are not just smaller than
32D IGF-IR/IRS1 cells. In the experiment shown in panel C, we
compared 32D IGF-IR/IRS1 cells (again in G2/M) in either
IGF-I or in IGF-I plus rapamycin. Rapamycin decreases the
size of the cells, almost to the level of untreated 32D IGF-IR
cells. Finally, in panel D, we show the size difference of 32D
IGF-IR cells in the G1 and G2 phases of the cell cycle. Since cells
in G2 are generally twice as big as cells in G1, this experiment
shows that modest differences in scattering revealed by FACS
analysis can actually equal almost a doubling in size.
Differentiation Markers—Since 32D IGF-IR cells proliferate
for at least 48 h, one can assume that the IGF-IR activates both
the proliferation program and the differentiation program, the
latter eventually prevailing (see Introduction). We have hy-
pothesized that IRS-1 extinguishes the differentiation pro-
gram, leaving the proliferation program intact. As a first ap-
proach to test this hypothesis, we have examined the
appearance of a known differentiation marker, the MPO
mRNA in our 2 cell lines. The results of one such experiment
are shown in Fig. 5, where we examined MPO mRNA levels in
cells in IL-3 or in IGF-I at various intervals after IL-3 with-
drawal. MPO mRNA levels remain high in 32D IGF-IR cells
24 h after IL-3 withdrawal and increase at 48 h. MPO mRNA
levels are decreased in 32D IGF-IR/IRS1 cells and diminish
further by 48 h. Thus, the hypothesis is supported by these
findings. 32D IGF-IR/IRS-1 cells do not seem to activate the
differentiation program, that is, instead, activated in 32D
IGF-IR cells. We have also examined 32D IGF-IR/IRS1 cells
treated with rapamycin, which induces differentiation (see
above). The MPO mRNA levels now increase even in 32D
IGF-IR/IRS1 cells (last two lanes of Fig. 5), especially at 48 h.
Effect of Okadaic Acid—We have determined the effect of
OKA on the growth and differentiation of 32D IGF-IR and 32D
IGF-IR/IRS-1 cells. OKA is a potent inhibitor of serine phos-
phatases (36), and the serine phosphatase PP2A interacts di-
rectly with p70S6K (37). Among the many effects of OKA, it
FIG. 3. Effect of rapamycin on p70S6K activation in 32D IGF-
IR/IRS-1 cells. 32D IGF-IR/IRS1 cells were incubated in serum-free
medium for 4 h. Samples treated with rapamycin were pre-incubated
with 10 ng/ml of rapamycin for 15 min before stimulation with IGF-I 20
ng/ml. The incubations were stopped at the times indicated (in min),
and the lysates obtained were run on four separate gel-SDS-PAGE. The
membranes were blotted with the three different anti-phospho-p70S6K
antibodies described in panels A, C, and E. After stripping, the filters
were re-blotted with an anti-p70S6K antibody to monitor the total levels
of protein (panels B, D, and F). The samples in panel G were run on a
7.5% gel to enhance the mobility shift of the total p70S6K (see previous
figures).
FIG. 4. Cell size analysis of 32D-derived cells. Cell size was
analyzed by FS as described under “Experimental Procedures.” The
differences in size are presented as the superimposed histograms gen-
erated by FACS analysis. Panel A gives a comparison between 32D
IGF-IR and 32D IGF-IR/IRS-1 cells in three different phases of the cell
cycle (48 h after IL-3 withdrawal and supplementation with IGF-I). The
lower panels (B–D) give three controls. Panel B, FS for the G2/M sub-
population of 32D IGF-IR cells in IL-3 or in IGF-I (48 h). Panel C, FS for
the G2/M subpopulation of 32D IGF-IR/IRS1 cells in IGF-I or in IGF-I
plus rapamycin (48 h). Panel D is a comparison of FS for the 32D IGF-IR
cells in the G1 or G2/M phases of the cell cycle (48 h in IGF-I). These
experiments were repeated three times.

























induces apoptosis, and its apoptotic effect is counteracted by
the IGF-IR (38). OKA also induces serine phosphorylation of
IRS-1 (39), which causes inhibition of IRS-1 signaling (40). We
reasoned that OKA ought to inhibit the activation of p70S6K,
reduce the growth and induce the differentiation of 32D IGF-
IR/IRS1 cells. Fig. 6 (panel A) shows that OKA inhibits the
proliferation of 32D IGF-IR/IRS1 cells, and that this inhibition
is complete at a concentration of only 20 nM.
At the same time, we examined the extent of differentiation
of 32D IGF-IR/IRS1 cells in the presence or absence of OKA. At
a concentration of 20 nM, OKA induces differentiation of 32D
IGF-IR/IRS1 cells (Fig. 6, panel B). The effect is only partial,
when compared with 32D IGF-IR cells (closed bars), but it is
nevertheless significant. Increasing the concentration of OKA
unfortunately results in massive cell death, which obscures its
differentiating effect. We monitored the effect of OKA on IRS-1,
by studying its shift in mobility (38, 39), due to the extensive
phosphorylation of serine residues. OKA induced a mobility
shift of IRS-1 in our cell lines, as expected (data not shown).
We tested the effect of OKA on the phosphorylation and
activation of p70S6K in 32D IGF-IR/IRS-1 cells. OKA inhibits
the long term phosphorylation of threonine 389 (Fig. 7, panel
A). Panel B shows the amounts of p70S6K in each lane. The
samples shown in panel C were run on a 7.5% gel (see above).
OKA causes a decrease in mobility shift of p70S6K, especially
visible at 30 min after IGF-I stimulation (panel C). The exper-
iments of Figs. 7 were repeated several times, with similar
results.
IL-3 Independence Test—In a previous paper (2), we reported
that 32D IGF-IR/IRS1 cells grew, in a medium supplemented
with 10% fetal bovine serum and IGF-I, for at least 4 days,
whereas 32D IGF-IR cells had stopped growing at 48 h and had
begun to differentiate. We have asked whether 32D IGF-IR/
IRS1 cells are transformed cells. The first prerequisite of a
transformed 32D cells is its ability to grow indefinitely in the
absence of IL-3 (41). To determine IL-3 independence, we
tested the cell lines after re-plating. For this experiment, we
also added as a control 32D IGF-IR cells transduced with the
vector used to introduce IRS-1 (empty vector). As described
under “Experimental Procedures,” the cell lines were grown for
4 days without IL-3 but with IGF-I, and the cell number was
determined. Then, the same number of viable cells from each
cell line was re-incubated in IL-3-deficient, IGF-I-supple-
mented medium. Cell number was determined after an addi-
tional 4 days in culture. The results are shown in Fig. 8. 32D
IGF-IR and 32D IGF-IR/vector cells grew in the first 4 days
after IL-3 withdrawal (albeit with considerable less efficiency
than 32D IGF-IR/IRS-1 cells) and showed differentiation (36%
and 37%, respectively). After re-plating, only a few cells (61% of
them differentiated) were left at the end of the experiment on
day 8. In contrast, 32D IGF-IR/IRS1 cells grew again in the
absence of IL-3, without any evidence of differentiation. These
experiments therefore show that 32D IGF-IR/IRS1 cells have
become IL-3-independent and can be passaged in its absence.
Finally, all these cell lines have repeatedly tested negative
FIG. 5. Expression of myeloperoxidase mRNA in 32D-derived
cells. RNAs were prepared from cells seeded in IL-3-free medium (0 h)
or supplemented with 50 ng/ml IGF-I (24 and 48 h) alone or in combi-
nation with rapamycin (10 ng/ml). The RNAs were subjected to North-
ern blot as described under “Experimental Procedures.” The autora-
diograph obtained after hybridization with the probe for the
myeloperoxidase mRNA is shown in panel A. The 28 S ribosomal RNA
stained with ethidium bromide is reported to monitor the total amount
of RNA present on the filter (panel B).
FIG. 6. Effect of okadaic acid on the proliferation and differ-
entiation of 32D-derived cells. 32D IGF-IR (closed bars) and 32D
IGF-IR/IRS-1 (gray bars) were seeded in IL-3-free medium supple-
mented with 50 ng/ml IGF-I at the density of 1 3 105 cells in 2 ml total
volume. 32D IGF-IR/IRS-1 were also incubated in 50 ng/ml IGF-I and
10 nM OKA (open bars) or 20 nM OKA (striped bars). Cells were ana-
lyzed for growth and differentiation after 4 and 6 days of culture. Panel
A, cell proliferation was evaluated by counting the total number of
viable cells. Panel B, Wright-Giemsa-stained cells were evaluated for
the presence of morphological characteristics of differentiation (per-
centage of bands and polymorphonuclear cells on the total number of
cells scored). A representative experiment (duplicate with range) is
shown.
FIG. 7. Effect of okadaic acid on p70S6K activation in 32D IGF-
IR/IRS-1 cells. 32D IGF-IR/IRS-1 cells were incubated in serum-free
medium for 4 h. Samples treated with OKA were pre-incubated with
500 nM OKA for 60 min before stimulation with IGF-I (20 ng/ml).
Control cells were incubated only with IGF-I. Lysates obtained at the
times indicated (in min) were run on three separate gels (SDS-PAGE)
and the membranes blotted with the three different anti-phospho-
p70S6K antibodies. For convenience, we show only the results obtained
with the anti-phosphothreonine 389 antibody (panel A) and the total
level of protein (panel B). The blot shown in panel C was run on a 7.5%
gel to enhance the mobility shift of the total p70S6K (see “Experimental
Procedures”).

























for mycoplasma. This is important, because Feng et al. (42)
have recently reported that mycoplasma infection induces ma-
lignant transformation of 32D cells.
Tumor Formation in Animals—IL-3 independence has been
often taken as a measure of transformation of 32D cells (41).
However, a more stringent criterion for transformation is the
ability to form tumors in animals. We tested both 32D IGF-IR
and 32D IGF-IR/IRS1 cells for their ability to form tumors in
nude mice (see “Experimental Procedures”). Because 32D cells
are of hemopoietic origin, and because they were injected in-
traperitoneally, we expected them to localize predominantly in
the abdominal organs, especially spleen and liver (which, inci-
dentally, is the major site of IGF-I production in the animal
body). The results are shown in Fig. 9, where we compare the
pathology of mice injected with either 32D IGF-IR cells and
32D IGF-IR/IRS-1 cells. However, the parental 32D cells be-
haved, as expected, like the 32D IGF-IR cells (data not shown).
32D IGF-IR/IRS1 cells form tumors in nude mice, causing
marked increases in weight of both liver and spleen (Fig. 9,
compare panels A and B). On average, the livers doubled their
weight, while the weight of spleen increased 10-fold. Histolog-
ically (Fig. 9), the structures of both liver and spleen are oblit-
erated by the infiltration of leukemic cells. Only remnants of
hepatocytes can be seen in the liver (compare panels C and D).
In the spleen, the small lymphocytes of the normal spleen
(panel F) have been replaced by larger leukemic cells (panel E).
32D IGF-IR/IRS-1 cells can also form tumors in syngeneic mice,
but only when the cells are injected intravenously (data not
shown). Therefore, even by the quite stringent criterion of
tumor formation in animals, 32D IGF-IR/IRS1 cells are
transformed.
DISCUSSION
As previously reported, in the absence of IRS-1, the IGF-IR
induces only a burst of cell proliferation (about 48 h), after
which, the cells (32D IGF-IR cells) undergo granulocytic differ-
entiation (Ref. 2 and this paper). The novel findings in this
report can be summarized as follows. 1) A comparison of sig-
naling between the 2 cell lines shows that in 32D IGF-IR/IRS1
cells, the phosphorylation of threonine 389 and threonine 421/
serine 424 of p70S6K is stronger and more sustained, when
compared with the 32D IGF-IR cells. 2) In support of a role of
p70S6K in the transformation of 32D IGF-IR/IRS1 cells, we
show that rapamycin, which inhibits the activation of p70S6K
(Refs. 29, 32, and 43, and this paper) causes differentiation of
32D IGF-IR/IRS1 cells. 3) The ectopic expression of IRS-1 and
the sustained activation of p70S6K result in an increase in cell
size of 32D IGF-IR/IRS-1 cells, increase that is inhibited by
rapamycin. 4) Despite the fact that, in the first 48 h, both 32D
IGF-IR and 32D IGF-IR/IRS1 cells proliferate very actively
(Ref. 11 and this paper), a differentiation marker, MPO mRNA,
is already prominent at 24 h in 32D IGF-IR cells. MPO mRNA
levels do not increase in 32D IGF-IR/IRS-1 cells, but they do so
in the same cells treated with rapamycin. Secondary findings
include the following. 5) OKA, which also inhibits the activa-
tion of p70S6K, causes differentiation of 32D IGF-IR cells. 6)
32D cells expressing both the IGF-IR and IRS-1 (32D IGF-IR/
IRS-1 cells) have a transformed phenotype, as evidenced by
IL-3 independent growth and the ability to form tumors in
animals.
There are several reports in the literature that cells in gen-
eral, and hemopoietic cells in particular, must undergo one or
two rounds of DNA synthesis before they can differentiate (5,
15). Therefore, it is not surprising that 32D IGF-IR cells do
grow for 48 h before they begin to differentiate. The question is
how IRS-1 can inhibit the differentiation program in these
cells, and actually transform them. It is generally assumed that
the IGF-IR and the insulin receptor use for mitogenesis 3 main
pathways (44–47). The first is through IRS-1 to PI-3 kinase to
p70S6K (16, 30); the second is through IRS-1 to Grb2 to Ras and
Erk, and the third one is from Shc to Grb2, to Ras again. Both
p70S6K and ERK are required for mitogenesis (17, 44, 48).
Although IGF-IR signaling is certainly more complicated than
this, this simplification gives an operational scheme for any
attempt to elucidate pathways involved in two different and
contradictory programs. The first exception to this scheme is
provided by the observation that the IGF-IR (but not the IR)
does not need IRS-1 for mitogenesis and survival in 32D cells
(2, 9–11), at least for the first 48 h. It seems that the IGF-IR
has pathways for protection from apoptosis, cell proliferation
and differentiation that are IRS-1-independent (2, 10) and are
not shared with the IR (11).
One reasonable target of IRS-1 is p70S6K, which is activated
by IRS-1 (16, 49), although it may be also activated by other
transducing molecules (50). In a hierarchical model of kinase
activation, the activation of p70S6K is apparently dependent on
the phosphorylation of a putative auto-inhibitory C terminus,
which causes a change in conformation, which, in turn, allows
the catalytic domain to be activated (28, 51). Our results show
that the presence of IRS-1 causes a sustained phosphorylation
of threonine 389, and of threonine 421/serine 424, phosphoryl-
ation that is shorter and less intense in 32D IGF-IR cells. This
difference is highly reproducible, and results also in a differ-
ence in the mobility of the p70S6K protein. A mobility shift of
p70S6K has often been taken as an indication of activation (16,
29, 52). In addition, phosphorylation of threonine 389 is largely
obliterated when 32D IGF-IR/IRS-1 cells are treated with ra-
pamycin, which induces differentiation. As mentioned above,
threonine 389 belongs to the group of serine/threonines of
p70S6K that are rapamycin-sensitive. Indeed, they were origi-
nally considered to be the only residues that were rapamycin-
sensitive, while the residues in the C terminus (like threonine
421 and serine 424) were considered insensitive (29, 31, 32).
More recent reports have questioned this difference (33–35).
FIG. 8. Growth of 32D-derived cells in the absence of interleu-
kin-3. 32D IGF-IR (striped bars), 32D IGF-IR/vector (open bars), and
32D IGF-IR/IRS-1 cells (closed bars) were seeded in IL-3-free medium
supplemented with 50 ng/ml IGF-I at the density of 5 3 10 4 cells/ml in
a total volume of 2 ml. At day 4 viable cells were counted by trypan blue
exclusion, and 10 3 10 4 cells for each cell line were re-plated in 2 ml of
fresh IL-3-free medium with IGF-I (50 ng/ml). Cells were counted after
4 additional days for a total of 8 days of culture. Data are the average
of three separate experiments (with standard deviations).

























Incidentally, the induction of differentiation in 32D IGF-IR/
IRS-1 cells by rapamycin, a specific inhibitor (through mTOR)
of p70S6K (28), at concentrations that do not cause apoptosis,
provides evidence for a role of p70S6K in this model that goes
beyond a simple correlative finding.
In no way should our findings be construed as indicating that
p70S6K activation is not needed for proliferation of 32D cells.
The abundant literature on the subject shows that p70S6K is
required for the G1 to S transition (17), and indeed we show
that p70S6K is activated in both 32D IGF-IR and 32D IGF-IR/
IRS1 cells, that proliferate for the first 48 h. The difference
between our two cell lines is in the sustained stimulation of
p70S6K, a difference confirmed when the 32D IGF-IR/IRS1 cells
are induced to differentiate by rapamycin (or OKA). One cor-
ollary of these findings is that the IGF-IR can activate p70S6K
in the absence of IRS-1. The human insulin receptor fails to
activate p70S6K in the absence of IRS-1 (52). These studies also
emphasize the need to examine phosphorylation of p70S6K with
different phosphospecific antibodies and at different intervals
after stimulation. Weng et al. (34) carried out an extensive
study of p70S6K phosphorylation and activation, using several
phosphospecific antibodies. Their time courses (their Fig. 2)
extended to 30 min after insulin stimulation, with no sugges-
tion of a decrease at that time (unless rapamycin or wortman-
nin were added). The cells used by Weng et al. (34) were
CHO-IR cells, which have IRS-1 and overexpress the insulin
receptor. Han et al. (29) also looked at p70S6K activity at times
up to 1 h after stimulation, and showed that the inhibitor
SQ20006 caused inhibition. Our results seem to indicate that if
we had examined p70S6K phosphorylation only at 15 min after
IGF-I stimulation, the difference between the two cell lines
would have been much less convincing. It is only at later times
that differences emerge, and these differences are corroborated
by changes in mobility shifts.
As to the mechanism(s) by which IRS-1 and p70S6K bring
about the transformed phenotype, we have explored in this
paper two possibilities. The first possibility is an effect on cell
size. An effect of IGF-IR signaling on cell size was suggested by
the experiments of Surmacz et al. (53), who showed that IGF-I
could activate the ribosomal DNA promoter, and further sup-
ported by the finding that p70S6K knock-out mice are somewhat
smaller than their wild type littermates (54). But the impor-
tance of IRS-1 and p70S6K in cell size regulation was demon-
strated more rigorously by the recent reports that homologues
of both IRS-1 and the S6 kinase regulate cell size in Drosophila
(18, 19). We show here that cell size is increased in 32D IGF-
IR/IRS-1 cells, but not when the cells are treated with rapamy-
cin. The increase in the mean of the forward scatter is small but
highly reproducible, and, for a proper assessment, one should
compare our data with Fig. 2 of Bohni et al. (18). In this figure,
FIG. 9. Pathology of liver and
spleen in Mice injected with 32D IGF-
IR/IRS-1 cells. The animals and the cell
lines are described under “Experimental
Procedures”. Panel A, a representative
picture of liver, spleen, and kidneys from
nude mice injected with 32D IGF-IR/
IRS-1 cells. Panel B, same for mice in-
jected with 32D IGF-IR cells. Panel C,
histology of liver in mice injected with
32D IGF-IR/IRS-1 cells. Panel D, liver
section of animals injected with 32D
IGF-IR cells. Panels E and F, spleen sec-
tions of mice injected with 32D IGF-IR/
IRS1 or 32D IGF-IR cells, respectively.
All magnifications for histology are 3400.
The only tissues markedly increased in
weight in mice injected with the 32D IGF-
IR/IRS-1 cells were the liver and spleen.

























Bohni et al. (18) used, like us, FACS analysis to estimate the
effect of CHICO on cell size in Drosophila. Their difference
(also measured by forward scattering) was 10–14%, the same
difference we have noticed in our cells. Furthermore, our com-
parison of the G1 and G2 subpopulations of the same cell line
(Fig. 4, panel D) shows that the small difference revealed by
forward scattering reflects a considerable difference in actual
size.
The second possibility (the two possibilities are not mutually
exclusive) is based on a simple hypothesis. This hypothesis
calls for the IGF-IR to send signals for two separate programs:
differentiation and mitogenesis (see above). In this scenario,
the main function of IRS-1 would be to extinguish the differ-
entiation program. It has been reported that certain markers of
differentiation in hemopoietic cells can be detected very early,
while the cells are still proliferating (55). If our hypothesis is
correct, a marker of differentiation would be visible at early
times in 32D IGF-IR cells, but not in 32D IGF-IR/IRS1 cells.
Our results with an early differentiation marker, the MPO
mRNA, are compatible with this hypothesis. The levels of MPO
mRNA are high in 32D IGF-IR cells at 24 h after IL-3 with-
drawal (with the cells rapidly proliferating), while they are
much lower in 32D IGF-IR/IRS-1 cells. In further support of
our hypothesis is the finding that MPO mRNA is also increased
in 32D IGF-IR/IRS-1 cells treated with rapamycin. Inciden-
tally, 32D IGF-IR/IRS1 cells have not lost the capacity to un-
dergo granulocytic differentiation. They are induced to do so
not only by OKA and rapamycin, but also by granulocyte col-
ony-stimulating factor (data not shown).
Since PI 3-kinase plays an important role in activation of
p70S6K (see above), it is reasonable to ask whether inhibitors of
PI 3-kinase have any effect on the growth of these cells. Addi-
tion of PI 3-kinase inhibitors has little effect on the growth of
32D IGF-IR cells (10, 11). It seems therefore that the IGF-IR
can stimulate growth by a mechanism by passing PI 3-kinase.
However, Akt is weakly but reproducibly activated by IGF-I in
32D IGF-IR cells (2). An obvious next step is to determine
whether the activation of p70S6K by the IGF-IR, in the absence
of IRS-1, may directly involve PDK1 (28).
An intriguing conclusion of this paper is that IRS-1 can make
the difference between terminal differentiation (and death) and
malignant transformation in 32D cells expressing the IGF-IR.
Although 32D IGF-IR cells are stimulated to proliferate by
IGF-I for the first 48 h (Ref. 11 and this paper), only 32D
IGF-IR/IRS1 cells can form tumors in nude and syngeneic mice
(or grow continuously in the absence of IL-3). There is often a
discrepancy between decreased growth factor requirements
and ability to form tumors in experimental animals (56). For
this reason, we wish to document here that the 32D IGF-IR/
IRS1 cells not only have lost the IL-3 requirement, but are also
capable of forming tumors in mice.
Finally, there are two other considerations that should be
discussed at this point. The first is the use of a dominant
negative mutants of p70S6K. It would have confirmed the data
obtained with rapamycin, but the problem with dominant neg-
ative mutants of p70S6K is the existence of a similar kinase,
S6K2, that can, at least partially, replace the p70S6K function
(28, 54). A second legitimate concern is the connection between
an effect seen at 60 min (sustained activation of p70S6K) and an
event (differentiation) that materializes only after 48 h or even
later. This is a problem with all signal transduction events
when one wishes to correlate them to later processes, such as
proliferation or transformation. However, Rose et al. (57), in an
elegant experiment, have shown that some transducing signals
are required throughout the cell cycle, while other are required
only for the first 15 min after growth factor stimulation. We
may also add that the extinction of the differentiation program
(see Fig. 5) must occur early after IGF-I stimulation.
In conclusion, our experiments offer a valuable model for the
study of transformation versus differentiation in murine hemo-
poietic cells expressing the IGF-IR. The presence or absence of
IRS-1 determines whether the cells will transform or differen-
tiate, respectively. The mechanism requires the sustained ac-
tivation of the p70S6K pathway. We would like to speculate (see
above) that the main function of IRS-1 in this model is to
inhibit the activation of the differentiation program, resulting
in continuous cell proliferation. Our results with the MPO
mRNA suggest that this hypothesis may be correct. It is there-
fore possible that the differences reported in this paper be-
tween 32D IGF-IR cells and 32D IGF-IR/IRS-1 cells may al-
ready be programmed in the early stages of IGF-I stimulation,
before the fate of the cells actually diverges. The next step
would be to investigate how the various transcription factors
that are involved in myeloid differentiation are affected by
IRS-1 in the various conditions described in this paper.
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